[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20211034T1 - 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze - Google Patents

2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze Download PDF

Info

Publication number
HRP20211034T1
HRP20211034T1 HRP20211034TT HRP20211034T HRP20211034T1 HR P20211034 T1 HRP20211034 T1 HR P20211034T1 HR P20211034T T HRP20211034T T HR P20211034TT HR P20211034 T HRP20211034 T HR P20211034T HR P20211034 T1 HRP20211034 T1 HR P20211034T1
Authority
HR
Croatia
Prior art keywords
ring
nitrogen
membered
oxygen
sulfur
Prior art date
Application number
HRP20211034TT
Other languages
English (en)
Inventor
Nadia AHMAD
Dean Boyall
Jean-Damien Charrier
Chris Davis
Rebecca Davis
Steven Durrant
Gorka ETXEBARRIA I JARDI
Damien Fraysse
Juan-Miguel Jimenez
David Kay
Ronald Knegtel
Donald MIDDELTON
Michael ODONNELL
Maninder PANESAR
Francoise Pierard
Joanne Pinder
David Shaw
Pierre-Henri Storck
John Studley
Heather Twin
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of HRP20211034T1 publication Critical patent/HRP20211034T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (30)

1. Spoj, koji ima formulu I-B: [image] ili njegova farmaceutski prihvatljiva sol, naznačeno time, u kojem (I): R1 je neovisno odabran od fluoro, kloro ili -C(J1)2CN; J1 je neovisno odabran od H ili C1-2alkila; ili dvije pojave J1, skupa s atomom ugljika za kojeg su vezani, tvore po izboru supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran od H; kloro; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkila; -CN; ili C1-3alifatskog lanca pri čemu se do dvije jedinice metilena iz alifatskog lanca po izboru mogu zamijeniti sa -O-, -NR-, -C(O)- ili -S(O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L1 je po želji supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabranih između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D se neovisno bira između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-člani potpuno zasićeni ili djelomično nezasićeni biciklički prsten s 1-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -N (R°) 2; 3-6-eročlanog karbociklila; 3-6-eročlanog heterociklila koji ima 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-4alkilni lanac u kojem do dvije metilenske jedinice alkilnog lanca se po izboru zamjenjuju sa -O-, -NR-, -C (O) - ili -S (O)n; svaki JG je po izboru supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su vezani, čine 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dvije pojave JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prestenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika, ili sumpora; L3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog sa 1-3 pojavljivanja halo; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po želji zamijenjene sa - O-, -NR-, -C (O) - ili -S (O)n; N je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (II): R1 je neovisno odabran od fluoro, kloro ili -C (J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore poželji supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkila; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L1 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlanim ne-aromatskim prstenom koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; L3 je H; C1-3alifat; ili CN; prsten D je neovisno odabran između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-eročlani potpuno zasićeni ili djelomično nezasićeni biciklički prsten s 1-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -CN; -N (R°)2; → O; 3-6-eroeročlani karbociklil; 3-6-eročlani heterociklil koji ima 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-4alkilni lanac u kojem do dvije metilenske jedinice alkilnog lanca se po izboru zamjenjuju sa -O-, -NR-, -C (O) - ili -S (O)n; svaki JG je po izboru supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom za kojeg su vezani, čine 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prstenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana od kisika, dušika ili sumpora; n je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (III): R1 je neovisno odabran između fluoro, kloro ili -C (J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore po želji supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkil; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L1 je po želji supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlanim ne-aromatskim prstenom koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C (O) - ili -S (O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D se neovisno bira između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-eročlanog potpuno zasićenog ili djelomično nezasićenog bicikličkog prstena koji ima 1-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -CN; -N (R°)2; 3-6-eročlanog karbociklila; 3-6-eročlanog heterociklila koji ima od 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-4alkilnog lanca pri čemu gore navedene do dvije metilenske jedinice alkilnog lanca se po izboru zamjenjuju sa -O-, -NR-, -C (O) - ili -S(O)n; svaki JG je po želji supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su pridruženi, tvore 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prestenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika, ili sumpora; n je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (IV): R1 je neovisno odabran između fluoro, kloro ili -C(J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore po izboru supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkila; -CN; ili C1-3alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene sa -O-, -NR-, -C(O) - ili -S(O)n; L1 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene s -O-, -NR-, -C(O) - ili -S(O)n; svaki L1 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; L2 je H; 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili C1-6alifatski lanac u kojem su do dvije metilenske jedinice alifatskog lanca po izboru zamijenjene s -O-, -NR-, -C(O)- ili -S(O)n; svaki L2 je po izboru supstituiran s C1-4alifatom; -CN; halo; -OH; ili 3-6-eročlani ne-aromatski prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D se neovisno bira između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 7-12-eročlanog potpuno zasićenog ili djelomično nezasićenog bicikličkog prstena s 1-5 heteroatoma odabranih između kisika, dušika ili sumpora; JG je neovisno odabran između halo; -N(R°)2; 3-6-eročlanog karbociklila; 3-6-eročlanog heterociklila koji ima 1-2 heteroatoma odabrana između kisika dušika ili sumpora; ili halkilni lanac u kojem do dvije metilenske jedinice alkilnog lanca se po izboru szamjenjuju s -O-, -NR-, -C(O)- ili -S(O)n; svaki JG je po izboru supstituiran s 0-2 pojavljivanja JK, dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su pridruženi, čine 3-6-eročlani prsten s 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prestenski sustav; JK je 3-7-eročlani aromatski ili ne-aromatski prsten koji ima 0-2 heteroatoma odabrana od kisika, dušika ili sumpora; n je 0, 1 ili 2; i R i R° su H ili C1-4alkil; ili: u kojem (V): R1 je neovisno odabran između fluoro, kloro ili -C (J1)2CN; J1 je neovisno odabran između H ili C1-2alkila; ili dva pojavljivanja J1, zajedno s atomom ugljika na koji su vezani, tvore po želji supstituirani 3-4-eročlani karbociklički prsten; R3 je neovisno odabran između H; klor; fluoro; C1-4alkila po izboru supstituiranog s 1-3 pojavljivanja halo; C3-4cikloalkil; ili -CN; L1 je po izboru supstituirani C1-6alifat; L2 je po izboru supstituirani C1-6alifat; ili L1 i L2, zajedno s dušikom na koji su vezani, čine prsten D; prsten D je po izboru supstituiran s 0-5 pojavljivanja JG; prsten D je neovisno odabran između 3-7-eročlanog heterociklilnog prstena koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora; ili 8-12-eročlanog potpuno zasićenog ili djelomično nezasićenog bicikličkog prstena s 0-5 heteroatoma odabrana između kisika, dušika ili sumpora; JG je neovisno odabran između C1-4alkila, -N (R°)2 ili 3-5-eročlanog karbociklila; ili dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prstenski sustav; i R° je H ili C1-4alkil.
2. Spoj u skladu s bilo kojim od patentnih zahtjeva 1(I) do 1(IV), naznačeno time, u kojem je (I) R1 fluoro; ili: u kojem je (II) R1 -CH2CN; ili: u kojem je (III) R1 kloro.
3. Spoj u skladu s patentnim zahtjevom 1 do 2(II), naznačeno time, što je R3 neovisno odabran od H, kloro, fluoro, ciklopropila ili C1-4alkila.
4. Spoj u skladu s patentnim zahtjevom 3, naznačeno time, što je (I) R3 neovisno odabran od H, kloro ili fluoro; ili: u kojem je (II) R3 H; ili: u kojem je (III) R3 kloro; ili: u kojem je (IV) R3 fluoro.
5. Spoj u skladu s patentnim zahtjevom 4, naznačeno time, što su L1 i L2 H; -(C1-3alkil)O(C1-2alkil); -(C1-3alkil)N(C1-2alkil)2; C1-4alkil; azetidinil; piperidinil; oksitanil ili pirolidinil.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačeno time, što L1 and L2 zajedno s dušikom za kojeg su vezani, tvore prsten D.
7. Spoj u skladu s patentnim zahtjevom 6, naznačeno time, što je prsten D 3-7-eročlani heterociklički prsten koji ima 1-2 heteroatoma odabrana od kisika, dušika ili sumpora.
8. Spoj u skladu s patentnim zahtjevom 7, naznačeno time, što je (I) prsten D neovisno odabran između piperazinila, piperidinila, morfolinila, tetrahidropiranila, azetidinila, pirolidinila ili 1,4-diazepanila; po izboru gdje je prsten D piperazinil, piperidinil, 1,4-diazepanil, pirolidinil ili azetidinil; po izboru pri čemu je prsten D piperazinil ili piperidinil; ili: gdje je (II) prsten D 8-12-eročlani potpuno zasićeni ili djelomično nezasićeni biciklički prsten koji ima 0-5 heteroatoma odabrana između kisika, dušika ili sumpora; po izboru gdje je prsten D oktahidropirolo[1,2-a] pirazin ili oktahidropirolo [3,4-c] pirol.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 7 i 8, naznačeno time, što JG je halo, C1-4alkil, -O (C1-3alkil), C3-6cikloalkil, 3-6-eročlani heterociklil, -NH (C1-3alkil), -OH ili -N (C1-4alkil)2; po izboru gdje JG je metil, -N(C1-4alkil)2, etil, -O(C1-3alkil), ciklopropil, oksetanil, ciklobutil, pirolidinil, piperidinil ili azetidinil; po izboru pri čemu je JG metal, -O (C1-3alkil), oksetanil, pirolidinil, piperidinil ili azetidinil; po izboru pri čemu je JG metil.
10. Spoj u skladu s patentnim zahtjevom 8, naznačeno time, što dva pojavljivanja JG, zajedno s prstenom D, tvore 6-10-eročlani zasićeni ili djelomično nezasićeni premošteni prstenski sustav; proizvoljno pri čemu je premošteni prstenski sustav 1,4-diazabiciklo[3.2.2]nonan, 1,4-diazabiciklo[3.2.1] oktan ili 2,5-diazabiciklo [2.2.1] heptan.
11. Spojevi u skladu s bilo kojim patentnim zahtjevom 7 i 8 (I), naznačeno time, što dva pojavljivanja JG na istom atomu, zajedno s atomom kojem su pridruženi, tvore 3-6-eročlani prsten koji ima 0-2 heteroatoma odabrana između kisika, dušika ili sumpora; po izboru pri čemu se prsten koji nastaje dvjema pojavama JG na istom atomu bira između oksetanila ili ciklopropila.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačeno time, što je neovisno odabran između: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] ili odabran od: [image] [image] ili njegova farmaceutski prihvatljiva sol.
13. Farmaceutski pripravak, naznačeno time, što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12 i farmaceutski prihvatljiv nosač.
14. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačeno time, što se koristi u liječenju karcinoma kod pacijenta.
15. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevom 14, naznačeno time, što uporaba nadalje obuhvaća davanje navedenom pacijentu dodatnog terapijskog sredstva neovisno odabranog između sredstva koje oštećuje DNA; pri čemu je navedeno dodatno terapijsko sredstvo prikladno za bolest koja se liječi; i navedeno dodatno terapijsko sredstvo daje se zajedno sa rečenim spojem u obliku jednog doziranja ili odvojeno od rečenog spoja kao dio višestrukog oblika doziranja; po izboru: pri čemu je (I) spomenuto sredstvo koje oštećuje DNA odabrano liječenjem kemoterapijom ili zračenjem; po izboru gdje je sredstvo za oštećenje DNA sredstvo za alkiliranje odabrano od Temozolomida; ili: u kojem je (II) navedeno sredstvo za oštećivanje DNA neovisno odabrano između ionizirajućeg zračenja, radiomimetičkog neokarzinostatina, platinirajućeg sredstva, inhibitora Topo I, inhibitora Topo II, antimetabolita, alkilirajućeg sredstva, alkil sulfonata ili antibiotika; po izboru pri čemu je (i) navedeno sredstvo za oštećivanje DNA neovisno odabrano između ionizirajućeg zračenja, sredstva za platinizaciju, inhibitora Topo I, inhibitora Topo II ili antibiotika; ili: pri čemu je (ii) navedeno sredstvo za oštećivanje DNA neovisno odabrano između ionizirajućeg zračenja, sredstva za platiniranje, inhibitora Topo I, inhibitora Topo II, antimetabolita, sredstva za alkiliranje ili alkil sulfonati; po izboru: pri čemu (a) je navedeno sredstvo za platiniranje neovisno odabrano između Cisplatina, Oksaliplatina, Karboplatina, Nedaplatina, Lobaplatina, Triplatin tetranitrata, pikoplatina, satraplatina, ProLindaca i Aroplatina; navedeni inhibitor Topo I odabran je između Camptothecina, Topotecana, Irinotecan / SN38, Rubitecana i Belotecana; navedeni inhibitor Topo II odabran je između Etopozida, Daunorubicina, Doksorubicina, Aclarubicina, Epirubicina, Idarubicina, Amrubicina, Pirarubicina, Valrubicina, Zorubicina i Tenipozida; navedeni antimetabolit je odabran između Aminopterina, Metotreksata, Pemetrekseda, Raltitrekseda, Pentostatina, Kladribina, Klofarabina, Fludarabina, Tioguanina, Merkaptopurina, Fluorouracila, Kapecitabina, Tegafura, Carmofura, Floxuridinacita, Citridekitara, Gemidrata, Klorafurina navedeno alkilirajuće sredstvo odabrano je iz mehloretamina, ciklofosfamida, ifosfamida, trofosfamida, klorambucila, melfalana, prednimustina, bendamustina, uramustina, estramustina, karmustina, Lomustina, Semustina, Fotemustina, Nimustina, Treptomansulfana, Ranimustfanola, Ranimustfan Triazikiona, Trietilenmelamina, Procarbazina, Dacarbazina, Temozolomida, Altretamina, Mitobronitola, Actinomycina, Bleomycina, Mitomycina i Plicamycina; po izboru: pri čemu (aa) navedeno sredstvo za platiniranje je neovisno odabrano između Cisplatina, Oksaliplatina, Karboplatina, Nedaplatina ili Satraplatina; navedeni inhibitor Topo I odabran je između kamptotecina, topotekana, irinotekana / SN38, rubitekana; spomenuti inhibitor Topo II odabran je između Etopozida; navedeni antimetabolit je odabran između metotreksata, pemetrekseda, tioguanina, fludarabina, kladribina, citarabina, gemcitabina, 6-merkaptopurina ili 5-fluorouracila; spomenuto sredstvo za alkiliranje odabire se između dušične gorušice, nitroso-uree, triazena, alkil sulfonata, prokarbazina ili aziridina; a spomenuti antibiotik odabran je iz obitelji Hydroxyurea, Anthracyclines, Anthracenediones ili Streptomyces; ili: pri čemu se (bb) navedeno sredstvo za oštećenje DNA neovisno bira između sredstva za platiniranje ili ionizirajućeg zračenja; proizvoljno gdje je dodatno terapijsko sredstvo Gemcitabin a tumor je karcinom gušterače; ili: pri čemu je (cc) kemoradijacija gemcitabin i zračenje; ili: pri čemu (b) je antimetabolit Gemcitabin; ili: pri čemu (c) sredstvo koje oštećuje DNA je ionizirajuće zračenje; ili: pri čemu (d) sredstvo za oštećenje DNA je sredstvo za platiniranje neovisno odabrano između Cisplatina ili Carboplatina;ili: pri čemu (e) sredstvo koje oštećuje DNA je inhibitor Topo II odabran između Etopozida; ili: pri čemu (f) sredstvo za oštećivanje DNA neovisno se bira između jednog ili više od sljedećeg: Cisplatin, Carboplatin, Gemcitabin, etopozida, temozolomida ili ionizirajuće zračenje; po izboru pri čemu su dodatna terapijska sredstva odabrana između jednog ili više od sljedećeg: Gemcitabin, Cisplatin ili Carboplatin i etopozid.
16. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim patentnim zahtjevom od 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevom 14 ili patentnim zahtjevom 15, naznačeno time, što je navedeni karcinom čvrsti tumor odabran od sljedećih karcinoma: oralno: usna šupljina, usne, jezik, usta, ždrijelo; srčani: sarkom (angiosarkom, fibrosarkom, rabdomiosarkom, liposarkom), miksom, rabdomiom, fibrom, lipom i teratom; pluća: bronhogeni karcinom (skvamozni ili epidermoidni, nediferencirane male stanice, nediferencirane velike stanice, adenokarcinom), alveolarni (bronhiolarni) karcinom, bronhijalni adenom, sarkom, limfom, hondromatozni hamartom, mezoteliom; gastrointestinalni: jednjak (skvamozni karcinom, grkljan, adenokarcinom, leiomiosarkom, limfom), želudac (karcinom, limfom, leiomiosarkom), gušterača (duktalni adenokarcinom, inzulin, glukagonom, gastrinom, karcinoidni tumori, tanki čvor, vipoma karcinom, limfom, karcinoidni tumori, Karposijev sarkom, leiomiom, hemangiom, lipom, neurofibroma, fibrom), crijevo ili debelo crijevo (adenokarcinom, tubularni adenom, vilozni adenom, hamartom, leiomiom), debelo crijevo, debelo crijevo-rektum, kolorektalni, rectum; genitourinarni trakt: bubreg (adenokarcinom, Wilmov tumor [nefroblastom], limfom), mokraćni mjehur i uretra (karcinom skvamoznih stanica, karcinom prijelaznih stanica, adenokarcinom), prostata (adenokarcinom, sarkom), testisi (seminom, teratom, embrionalni karcinom, teratokarcinom , horiokarcinom, sarkom, karcinom intersticijskih stanica, fibroma, fibroadenom, adenomatoidni tumori, lipomi); jetra: hepatom (hepatocelularni karcinom), kolangiokarcinom, hepatoblastom, angiosarkom, hepatocelularni adenom, hemangiom, bilijarni prolazi; Kosti: osteogeni sarkom (osteosarkom), fibrosarkom, maligni fibrozni histiocitom, hondrosarkom, Ewingov sarkom, maligni limfom (sarkom retikulumskih stanica), multipli mijelom, kordom malignog tumora divovskih stanica, osteokronfroma (osteokartilagični kostomandomagijski kostondomagijski kostomandomagijski kosto-bronhomagijski kosto-bronhomagijski kosto-bronhomagijski kosto-bronhomagijski kosto-magni kostoni bronhomani kosti tumori osteoma i divovskih stanica; živčani sustav: lubanja (osteom, hemangiom, granulom, ksantom, osteitis deformans), moždane ovojnice (meningioma, meningiosarkom, gliomatoza), mozak (astrocitom, meduloblastom, gliom, ependimom, germinom [pinealoma], glioblaligoma genomblastomoma multiformni glioblastomahnom, glioblastomahni multiform kongenitalni tumori), neurofibrom leđne moždine, meningiom, gliom, sarkom); ginekološki / ženski: maternica (karcinom endometrija), cerviks (karcinom vrata maternice, predtumorska cervikalna displazija), jajnici (karcinom jajnika [serozni cistadenokarcinom, mucinozni cistadenokarcinom, neklasificirani karcinom], tumori granulosatekalnih stanica, tumori Sertoli-Leydigoma, maligni tumori ćelija teratom), vulve (karcinom skvamoznih stanica, intraepitelna karcinom, adenokarcinom, fibrosarkom, melanom), vaginu (karcinom jasno stanica, karcinom skvamoznih stanica, botrioid sarkoma (embrionalni rabdomiosarkoma), jajovodi (karcinom), dojke, kože: maligni melanom, bazalni stanični karcinom, skvamozni karcinom, Karposijev sarkom, keratoakantom, molsni displastični nevusi, lipomi, angiomi, dermatofibromi, keloidi, psorijaza, štitnjača: papilarni karcinom štitnjače, folikularni karcinom štitnjače; tip 2B, obiteljski medularni karcinom štitnjače, feokromocitom, paragangliom i nadbubrežna glava nds: neuroblastoma: po izboru: pri čemu je spomenuti tumor odabran od karcinoma pluća ili gušterače; po izboru: pri čemu je spomenuti tumor karcinom pluća; proizvoljno: pri čemu je karcinom pluća ne-malih stanica ili karcinom pluća malih stanica; proizvoljno: pri čemu je (I) karcinom pluća malih stanica, a dodatna terapijska sredstva su cisplatin i etopozid; ili pri čemu (II) je karcinom pluća ne-malih stanica, a dodatna terapijska sredstva su gemcitabin i cisplatin; proizvoljno: pri čemu (i) je rak pluća ne-malih stanica stanični karcinom pluća nemalih stanica; ili: pri čemu (ii) je terapija karcinomom gemcitabin i zračenje.
17. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom zahtjevu 13, namijenjen upotrebi u skladu s patentnim zahtjevom 14 ili patentnim zahtjevom 15, naznačeno time, što je (I) navedeni karcinom odabran od karcinoma pluća, carcinoma glave i vrata, karcinoma gušterače, karcinoma želuca ili mozga; ili: pri čemu je (II) spomenuti karcinom odabran od karcinoma pluća ne-malih stanica, karcinoma pluća malih stanica, karcinoma gušterače, carcinoma žučnog trakta, karcinoma glave i vrata, karcinoma mokraćnog mjehura, karcinoma debelog crijeva, glioblastom, karcinoma jednjaka, karcinoma dojke, hepatocelularnog karcinoma ili karcinoma jajnika; po izboru pri čemu je tumor karcinoma dojke i dodatno terapijsko sredstvo je cisplatin; po izboru pri čemu je tumor trostruko negativni karcinom dojke.
18. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što u kombinaciji s dodatnim terapijskim sredstvom odabranim od Gemcitabina, terapije zračenjem ili zajedno s Gemcitabinom i terapijom zračenjem, služi za uporabu u liječenju raka gušterače.
19. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koje povećava osjetljivost stanica raka gušterače na terapiju karcinoma odabranu između kemoterapije ili zračenja; po želji: pri čemu je (I) kemoterapija gemcitabin; ili: pri čemu je (II) terapija karcinoma gemcitabin; ili: pri čemu je (III) terapija karcinoma zračenje.
20. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačeno time, što u kombinaciji s Gemcitabinom (100 nM) i / ili zračenjem (6 Gy) se koristi u liječenju koje inhibira fosforilaciju Chk1 (Ser 345) u stanici raka gušterače.
21. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koje senzibilizira stanice raka gušterače na kemoterapiju u kombinaciji s kemoterapijom.
22. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koji sadrži (I) radiosenzibilizirajuće hipoksične stanice raka gušterače u kombinaciji s terapijom zračenjem; ili: sadrži (II) senzibilizirajuće hipoksične stanice raka gušterače u kombinaciji s kemoterapijom.
23. Spoj, ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevima 21 ili 22, naznačeno time, što je spomenuta stanica karcinoma PSN-1, MiaPaCa-2 ili PancM stanica karcinoma.
24. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 12, naznačeno time, što se koristi u liječenju koje obuhvaća narušavanje kontrolnih točaka staničnog ciklusa uzrokovanih oštećenjem u kombinaciji s terapijom zračenjem i / ili Gemcitabinom.
25. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 12, naznačeno time, što se koristi u liječenju koje obuhvaća inhibiranje popravka oštećenja DNA rekombinacijom hemoglobina u stanici karcinoma gušterače u kombinaciji s terapijom zračenjem i / ili Gemcitabinom.
26. Spoj ili njegova farmaceutski prihvatljiva sol, za uporabu u skladu s patentnim zahtjevima 22 do 25, naznačeno time, što se spoj primjenjuje na stanicu raka gušterače; proizvoljno pri čemu su stanice raka gušterače izvedene iz stanične linije gušterače odabrane između PSN-1, MiaPaCa-2 ili Panc-1.
27. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačeno time, što se koristi u liječenju koje obuhvaća (I) liječenje karcinoma pluća ne-malih stanica u kombinaciji s jednim ili više sljedećih dodatnih terapijskih sredstava: Cisplatin ili Carboplatin , Etopozid i ionizirajuće zračenje; ili: (II) promicanje stanične smrti u stanicama raka; ili: (III) sprječavanje reparacije stanica od oštećenja DNA; ili: (IV) inhibiranje ATR u biološkom uzorku koji obuhvaća korak dovođenja u kontakt spoja prema bilo kojem od zahtjeva 1do 12 s navedenim biološkim uzorkom; proizvoljno pri čemu je navedeni biološki uzorak stanica; ili: (V) senzibilizaciju stanica na sredstva koji oštećuju DNA.
28. Spoj prema bilo kojem od zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom zahtjevu 13, za uporabu skladu s patentnim zahtjevima 15 do 27, naznačeno time, što je (I) navedena stanica stanica raka koja ima nedostatke u ATM signalnoj kaskadi; po izboru: pri čemu (i) je navedeni nedostatak promijenjeni izraz ili aktivnost ili jedan ili više ili slijedeće: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1 / BRIT1, CTIP ili SMC1; ili: pri čemu je (ii) spomenuti nedostatak promijenjena ekspresija ili aktivnost jednog ili više od sljedećeg: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 ili H2AX. pri čemu (II) rečeni karcinom, stanica raka, ili stanica ima nedostatak na proteinu za popravak bazne ekscizije; proizvoljno pri čemu proteini za popravak bazne ekscizije su: UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glikozilaze); APE1, APEX2 (AP endonukleaze); LIG1, LIG3 (DNA ligaze I i III); XRCC1 (dodatak LIG3); PNK, PNKP (polinukleotid kinaza i fosfataza); PARP1, PARP2 (poli (ADP-ribozne) polimeraze); PolB, PolG (polimeraze); FEN1 (endonukleaza) ili Aprataxin; po izboru, pri čemu je protein za popravak bazne ekscizije PARP1, PARP2 ili PolB; po izboru pri čemu je protein za popravak bazne ekscizije PARP1 ili PARP2.
29. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevima 14 do 27, naznačeno time, što je navedena stanica, tumorska stanica koja eksprimira onkogene koji oštećuju DNA; proizvoljno pri čemu je spomenuta tumorska stanica promijenila ekspresiju ili aktivnost jednog ili više od sljedećeg: K-Ras, N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Ciklin E, Ciklin A i Rb.
30. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 13, koji se koristi u skladu s patentnim zahtjevima 15 do 27, naznačeno time, što se nadalje sastoji od primjene na pacijenta dodatnog terapijskog sredstva u kojem navedeno sredstvo inhibira ili modulira protein za popravak bazne ekscizije; proizvoljno u kojem je protein za popravak bazne ekscizije odabran od UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases); APE1, APEX2 (AP endonukleaze); LIG1, LIG3 (DNA ligaze I and III); XRCC1 (dodatak LIG3); PNK, PNKP (polinukleotid kinaza i fosfataza); PARP1, PARP2 (Poli(ADP-Riboza) Polimeraza); PolB, PolG (polimeraze); FEN1 (endonukleaza) ili Aprataksin; po izobru pri čemu je protein za popravak bazne ekscizije odabran između PARP1, PARP2 ili PolB; po izboru, pri čemu je protein za popravak bazne ekscizije odabran između PARP1 ili PARP2; po izboru, pri čemu je navedeno sredstvo odabrano od Olapariba (također poznatog kao AZD2281 ili KU-0059436), Inipariba (također poznatog kao BSI-201 ili SAR240550), Velipariba (također poznatog kao ABT-888), Rucapariba (također poznatog kao PF-01367338 ), CEP-9722, INO-1001, MK-4827, E7016, BMN673 ili AZD2461.
HRP20211034TT 2012-12-07 2021-06-30 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze HRP20211034T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734726P 2012-12-07 2012-12-07
US201361787568P 2013-03-15 2013-03-15
US201361868132P 2013-08-21 2013-08-21
EP18212042.8A EP3486245B1 (en) 2012-12-07 2013-12-06 2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidine-3-carboxamid as inhibitor of atr kinase

Publications (1)

Publication Number Publication Date
HRP20211034T1 true HRP20211034T1 (hr) 2021-12-10

Family

ID=49877035

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20230476TT HRP20230476T1 (hr) 2012-12-07 2013-12-06 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje bolesti karcinoma
HRP20180859TT HRP20180859T1 (hr) 2012-12-07 2018-05-30 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
HRP20202058TT HRP20202058T1 (hr) 2012-12-07 2020-12-23 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje karcinoma
HRP20211034TT HRP20211034T1 (hr) 2012-12-07 2021-06-30 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HRP20230476TT HRP20230476T1 (hr) 2012-12-07 2013-12-06 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje bolesti karcinoma
HRP20180859TT HRP20180859T1 (hr) 2012-12-07 2018-05-30 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
HRP20202058TT HRP20202058T1 (hr) 2012-12-07 2020-12-23 Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za liječenje karcinoma

Country Status (31)

Country Link
US (8) US9340546B2 (hr)
EP (5) EP3486245B1 (hr)
JP (2) JP6401709B2 (hr)
KR (1) KR102213986B1 (hr)
CN (4) CN104903325B (hr)
AU (2) AU2013355124B2 (hr)
BR (1) BR112015012454B1 (hr)
CA (1) CA2892608C (hr)
CY (4) CY1120232T1 (hr)
DK (4) DK3808749T3 (hr)
ES (4) ES2946360T3 (hr)
FI (1) FI3808749T3 (hr)
HK (2) HK1209746A1 (hr)
HR (4) HRP20230476T1 (hr)
HU (4) HUE052808T2 (hr)
IL (2) IL239218A0 (hr)
LT (4) LT2941432T (hr)
ME (1) ME03036B (hr)
MX (1) MX368042B (hr)
NZ (2) NZ731337A (hr)
PL (3) PL3808749T3 (hr)
PT (4) PT3418281T (hr)
RS (4) RS57210B1 (hr)
RU (1) RU2689996C2 (hr)
SG (2) SG11201504467YA (hr)
SI (4) SI2941432T1 (hr)
SM (4) SMT202000713T1 (hr)
TR (1) TR201807740T4 (hr)
TW (1) TWI618706B (hr)
WO (1) WO2014089379A1 (hr)
ZA (2) ZA201503871B (hr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300862B (zh) 2008-12-19 2016-11-23 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
CA2850491C (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors
SI2833973T1 (en) 2012-04-05 2018-04-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and their combination therapy
KR102213986B1 (ko) 2012-12-07 2021-02-09 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN108715590B (zh) 2013-01-15 2022-03-08 因赛特公司 可用作pim激酶抑制剂的噻唑甲酰胺和吡啶甲酰胺化合物
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2014308703A1 (en) 2013-08-23 2016-03-24 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors
CN105934435B (zh) * 2013-12-06 2019-02-22 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物，其制备，及其放射性标记的衍生物
CN110590787A (zh) * 2014-06-05 2019-12-20 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
EP3157566B1 (en) 2014-06-17 2019-05-01 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
JP6633618B2 (ja) * 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
HRP20240644T1 (hr) * 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
PL3402532T3 (pl) 2016-01-11 2022-08-22 Celator Pharmaceuticals, Inc. Hamowanie ataksji-teleangiektazji i białka związanego z rad3 (atr)
BR112018016133A2 (pt) * 2016-02-16 2019-01-02 Massachusetts Inst Technology aglutinantes de max como moduladores de myc e usos dos mesmos
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201808830YA (en) 2016-04-06 2018-11-29 Lysosomal Therapeutics Inc Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
EP3535273A1 (en) 2016-11-02 2019-09-11 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
TW201840319A (zh) 2017-02-24 2018-11-16 德商拜耳廠股份有限公司 Atr激酶抑制劑與鐳-223鹽之組合
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
US10421765B2 (en) 2017-05-26 2019-09-24 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
SMT202400106T1 (it) 2017-07-13 2024-05-14 Univ Texas Inibitori eterociclici della atr chinasi
PT3658557T (pt) 2017-07-28 2024-09-11 Nimbus Lakshmi Inc Inibidores de tyk2 e usos dos mesmos
CA3071760A1 (en) 2017-08-04 2019-02-07 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
CN111886224B (zh) 2017-08-17 2024-07-23 德州大学系统董事会 Atr激酶的杂环抑制剂
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN107935918A (zh) * 2017-11-15 2018-04-20 山东潍坊润丰化工股份有限公司 一种百草枯的制备方法
BR112020010503A2 (pt) 2017-11-30 2020-10-20 Seattle Genetics, Inc. processo para a preparação de compostos ligantes a fármacos
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3720973A1 (en) 2017-12-08 2020-10-14 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
US20210196751A1 (en) * 2017-12-29 2021-07-01 Vertex Pharmaceuticals Incorporated Methods of cancer treatment using an atr inhibitor
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase
MX2021003263A (es) 2018-09-26 2021-05-12 Merck Patent Gmbh Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
JP2022505041A (ja) 2018-10-15 2022-01-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｎａアルキル化剤及びａｔｒ阻害剤を使用する併用療法
WO2020078788A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US20230119558A1 (en) * 2020-03-06 2023-04-20 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Dna damage repair genes in cancer
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
US20230226066A1 (en) 2020-06-18 2023-07-20 Merck Patent Gmbh Compounds for the treatment of viral infections
WO2022002243A1 (zh) * 2020-07-02 2022-01-06 江苏恒瑞医药股份有限公司 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
CN116283960A (zh) 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
WO2023116865A1 (zh) * 2021-12-23 2023-06-29 优领医药科技（上海）有限公司 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
CN115322143B (zh) * 2022-07-21 2023-07-14 安徽德诺医药股份有限公司 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
ATE208778T1 (de) 1995-05-09 2001-11-15 Basf Ag Pyrazolo- 1,5a)-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung
WO1997043267A1 (en) 1996-05-11 1997-11-20 Kings College London Pyrazines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
JPH10218881A (ja) 1997-02-03 1998-08-18 Pola Chem Ind Inc 新規なピロロピラゾロピリミジン誘導体
GB2323861B (en) 1997-02-05 2001-06-20 Sector Exhibiting Systems Artificial wall structure
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
WO2000004014A1 (fr) 1998-07-16 2000-01-27 Shionogi & Co., Ltd. Derives de pyrimidine manifestant une activite antitumorale
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2001302666A (ja) 1999-09-21 2001-10-31 Nissan Chem Ind Ltd アゾール縮合ヘテロ環アニライド化合物及び除草剤
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP2003516974A (ja) 1999-12-17 2003-05-20 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピラジンベースインヒビター
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US6420637B1 (en) 2001-01-29 2002-07-16 Asgrow Seed Company L.L.C. Plants and seeds of corn variety I389972
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
CA2465326C (en) 2001-11-01 2011-03-29 Icagen, Inc. Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel
PT1446387E (pt) 2001-11-21 2009-12-21 Pharmacia & Upjohn Co Llc Derivados de aril-1,4-pirazina substituídos
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
CA2475633C (en) 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
MXPA04010441A (es) * 2002-04-23 2005-02-14 Shionogi & Co Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo.
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN1701074A (zh) 2002-09-04 2005-11-23 先灵公司 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶
CN1701073B (zh) 2002-09-04 2011-06-22 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
ATE469903T1 (de) 2002-09-04 2010-06-15 Schering Corp Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
JP4695588B2 (ja) 2003-02-26 2011-06-08 スージェン， インク． プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物
BRPI0407834A (pt) 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
ATE402929T1 (de) 2003-03-11 2008-08-15 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CA2519677A1 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocycles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
US7807696B2 (en) 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
AU2005215379A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP2007523939A (ja) 2004-02-25 2007-08-23 ビーエーエスエフ　アクチェンゲゼルシャフト アゾロピリミジン化合物及び寄生性菌類を駆除するためのその使用
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2586375A1 (en) 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
US8003806B2 (en) 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
CA2587894A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
CN101102773B (zh) 2004-12-27 2010-10-27 爱尔康公司 治疗青光眼和其他rho激酶-介导疾病的氨基吡嗪类似物
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060156482A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
CA2605738C (en) 2005-04-25 2013-10-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel azaheterocyclic compounds as kinase inhibitors
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
BRPI0609802A2 (pt) 2005-05-20 2017-05-02 Alantos Pharmaceuticals Holding Inc composto, composição farmacêutica e uso de um composto
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
TWI333953B (en) 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
WO2007044441A2 (en) 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
JP5102212B2 (ja) * 2005-10-06 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
ATE517874T1 (de) 2005-10-21 2011-08-15 Exelixis Inc Pyrimidinone als modulatoren von caseinkinase ii (ck2)
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
ATE452635T1 (de) 2005-12-01 2010-01-15 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
ZA200804497B (en) 2005-12-22 2009-10-28 Alcon Res Ltd (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
AU2007231577B2 (en) 2006-03-22 2012-07-19 Vertex Pharmaceuticals Incorporated c-MET protein kinase inhibitors for the treatment of proliferative disorders
BRPI0709699A2 (pt) 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
CN101454314A (zh) 2006-03-31 2009-06-10 先灵公司 激酶抑制剂
WO2007139732A1 (en) 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
JP2009541323A (ja) 2006-06-22 2009-11-26 マリンクロット インコーポレイテッド 拡張された共役を有するピラジン誘導体およびその使用
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
AU2007304365A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
ES2631003T3 (es) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
US20080176870A1 (en) 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
UY30796A1 (es) 2006-12-15 2008-07-31 Bayer Schering Pharma Ag 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
AU2007338792B2 (en) 2006-12-20 2012-05-31 Amgen Inc. Substituted heterocycles and methods of use
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
JP5548119B2 (ja) 2007-04-10 2014-07-16 バイエル・クロップサイエンス・アーゲー 殺虫性アリールイソオキサゾリン誘導体
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2014661A1 (de) 2007-06-13 2009-01-14 Bayer CropScience AG Heterocyclisch substituierte Heterocyclyl-carbonsäurederivate
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JPWO2008156174A1 (ja) 2007-06-21 2010-08-26 大正製薬株式会社 ピラジンアミド化合物
EA201070058A1 (ru) 2007-06-26 2010-06-30 Лексикон Фармасьютикалз, Инк. Способы лечения опосредованных серотонином заболеваний и расстройств
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2009006580A1 (en) 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
BRPI0813426A2 (pt) 2007-07-19 2014-12-23 Lundbeck & Co As H Composto, composição farmacêutica, métodos para modular a atividade de um receptor p2x7, para tratar uma condição, para inibir a morte de células gangliônicas retinais, para promover perda de peso,e para determinar a presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, uso de composto ou sal ou hidrato do mesmo.
EA201000113A1 (ru) 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
CA2706946A1 (en) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
WO2009075790A1 (en) 2007-12-07 2009-06-18 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors for intra-articular application
AU2008343173A1 (en) * 2007-12-19 2009-07-09 Aj Park Pyrazolo [1,5-a] pyrimidines useful as JAK2 inhibitors
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
PT2247592E (pt) 2008-02-25 2011-11-03 Hoffmann La Roche Inibidores de pirrolpirazina-cinase
ATE519763T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
CA2712507A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
EP2313414B1 (en) 2008-07-08 2015-11-04 Intellikine, LLC Kinase inhibitors and methods of use
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
CA2732520A1 (en) 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2010034738A2 (en) 2008-09-24 2010-04-01 Basf Se Pyrazole compounds for controlling invertebrate pests
MX2011004188A (es) 2008-10-21 2011-06-09 Vertex Pharma Inhibidores de la proteina cinasa c-met.
CA2740792C (en) 2008-10-31 2016-06-21 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
WO2010063634A1 (en) 2008-12-05 2010-06-10 F. Hoffmann-La Roche Ag Pyrrolopyrazinyl urea kinase inhibitors
CN102300862B (zh) 2008-12-19 2016-11-23 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
RU2529860C2 (ru) 2009-01-30 2014-10-10 Тояма Кемикал Ко., Лтд. Производное n-ацилантраниловой кислоты или его соль
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
SG173639A1 (en) 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX2012000711A (es) 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
WO2011022439A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
CN102473224B (zh) 2009-12-22 2016-10-12 英特尔公司 提供安全应用执行的方法和装置
CN102869661B (zh) 2010-03-18 2015-08-05 韩国巴斯德研究所 抗感染化合物
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
WO2011121096A1 (en) 2010-03-31 2011-10-06 Dkfz Deutsches Krebsforschungszentrum PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS
AU2011236510A1 (en) 2010-04-08 2012-10-11 Zoetis Llc Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピラジン
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2011143422A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of atr kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN102906095A (zh) 2010-05-20 2013-01-30 弗·哈夫曼-拉罗切有限公司 作为syk和jak抑制剂的吡咯并吡嗪衍生物
KR20130083386A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-ｂ]피라진-7-카복스아마이드 유도체 및 ＪＡＫ 및 ＳＹＫ 억제제로서의 그의 용도
WO2011163527A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
RU2604062C2 (ru) 2010-07-13 2016-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
CA2817968C (en) 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
CN103534255B (zh) 2010-12-08 2016-12-21 美国健康及人类服务部 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
MX2013013331A (es) 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (hr) 2011-09-30 2015-08-21 Vertex Pharma
CA2850491C (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776419B1 (en) 2011-11-09 2016-05-11 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP6345645B2 (ja) 2012-04-02 2018-06-20 サイトキネティックス， インコーポレイテッド 横隔膜機能を向上させるための方法
SI2833973T1 (en) 2012-04-05 2018-04-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and their combination therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
JP6027230B2 (ja) 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用
EP2864338B1 (en) 2012-05-23 2016-12-14 Savira Pharmaceuticals GmbH 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20150014506A (ko) 2012-05-23 2015-02-06 사피라 파르마슈티칼즈 게엠베하 바이러스성 질환의 치료, 개선 또는 예방에서 유용한 7-옥소-4,7-디하이드로-피라졸로[1,5-a]피리미딘 유도체
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014023691A1 (en) 2012-08-06 2014-02-13 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014025850A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic amidine derivatives as hiv attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
ES2616432T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de alquenos tricíclicos como inhibidores de la unión del VIH
JP2015530990A (ja) 2012-08-17 2015-10-29 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺虫剤および殺ダニ剤としてのアザインドールカルボキサミドおよびアザインドールチオカルボキサミド
CN104583197B (zh) 2012-08-24 2017-05-17 霍夫曼-拉罗奇有限公司 新型双环吡啶衍生物
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
CN108440571B (zh) 2012-10-22 2022-11-04 希望之城 Etp衍生物
BR112015003160A2 (pt) 2012-10-24 2017-07-04 Becton Dickinson Co corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos
KR102213986B1 (ko) 2012-12-07 2021-02-09 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US20150158868A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN105934435B (zh) 2013-12-06 2019-02-22 沃泰克斯药物股份有限公司 用作atr激酶抑制剂的化合物，其制备，及其放射性标记的衍生物
CN110590787A (zh) 2014-06-05 2019-12-20 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
EP3157566B1 (en) 2014-06-17 2019-05-01 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors

Also Published As

Publication number Publication date
EP4190786A1 (en) 2023-06-07
CN107501275B (zh) 2019-11-22
TWI618706B (zh) 2018-03-21
RS62174B1 (sr) 2021-08-31
DK3418281T3 (da) 2020-12-07
HRP20230476T1 (hr) 2023-07-21
IL263262B (en) 2019-07-31
SI3486245T1 (sl) 2021-09-30
TW201434839A (zh) 2014-09-16
IL239218A0 (en) 2015-07-30
SI3418281T1 (sl) 2021-02-26
LT3418281T (lt) 2021-01-11
US9650381B2 (en) 2017-05-16
RS57210B1 (sr) 2018-07-31
US11117900B2 (en) 2021-09-14
PL3486245T3 (pl) 2021-11-08
NZ630457A (en) 2017-05-26
KR20150091171A (ko) 2015-08-07
ES2946360T3 (es) 2023-07-17
MX2015007101A (es) 2015-09-29
CY1124291T1 (el) 2022-07-22
SMT202000713T1 (it) 2021-03-15
EP2941432A1 (en) 2015-11-11
PL3808749T3 (pl) 2023-07-10
CN107501274B (zh) 2019-11-22
CN107629059A (zh) 2018-01-26
RS61319B1 (sr) 2021-02-26
NZ731337A (en) 2019-02-22
HUE037371T2 (hu) 2018-08-28
FI3808749T3 (fi) 2023-05-31
RU2689996C2 (ru) 2019-05-30
AU2018204431B2 (en) 2020-04-02
RU2015127079A (ru) 2017-01-10
CN104903325B (zh) 2017-10-20
US9718827B2 (en) 2017-08-01
BR112015012454A8 (pt) 2019-10-01
ES2669423T3 (es) 2018-05-25
AU2013355124B2 (en) 2018-03-22
JP2016501244A (ja) 2016-01-18
PT3808749T (pt) 2023-06-07
CN107501275A (zh) 2017-12-22
AU2018204431A1 (en) 2018-07-05
HRP20202058T1 (hr) 2021-02-19
MX368042B (es) 2019-09-17
TR201807740T4 (tr) 2018-06-21
LT3808749T (lt) 2023-06-12
CA2892608A1 (en) 2014-06-12
SG11201504467YA (en) 2015-07-30
SMT202100425T1 (it) 2021-09-14
IL263262A (en) 2018-12-31
CY1120232T1 (el) 2019-07-10
US10787452B2 (en) 2020-09-29
CY1123702T1 (el) 2022-03-24
SMT201800279T1 (it) 2018-07-17
WO2014089379A9 (en) 2015-01-15
KR102213986B1 (ko) 2021-02-09
HUE052808T2 (hu) 2021-05-28
ZA201605990B (en) 2019-12-18
EP3486245A1 (en) 2019-05-22
US20140249157A1 (en) 2014-09-04
ES2842876T3 (es) 2021-07-15
HUE061909T2 (hu) 2023-08-28
LT3486245T (lt) 2021-08-25
US20140163000A1 (en) 2014-06-12
US20180155346A1 (en) 2018-06-07
HK1209746A1 (en) 2016-04-08
EP3486245B1 (en) 2021-04-28
PT3486245T (pt) 2021-07-30
US20230271963A1 (en) 2023-08-31
US20180072735A1 (en) 2018-03-15
JP2018087213A (ja) 2018-06-07
US20210047333A1 (en) 2021-02-18
SI3808749T1 (sl) 2023-07-31
HUE055618T2 (hu) 2021-12-28
EP2941432B1 (en) 2018-03-07
SMT202300157T1 (it) 2023-07-20
HRP20180859T1 (hr) 2018-07-13
US20200140441A1 (en) 2020-05-07
US20160347754A1 (en) 2016-12-01
BR112015012454A2 (pt) 2017-07-11
EP3418281A1 (en) 2018-12-26
DK2941432T3 (en) 2018-06-14
HK1217190A1 (zh) 2016-12-30
EP3418281B1 (en) 2020-09-30
US10392391B2 (en) 2019-08-27
DK3486245T3 (da) 2021-07-19
SI2941432T1 (en) 2018-07-31
CA2892608C (en) 2021-10-19
SG10201606373XA (en) 2016-09-29
DK3808749T3 (da) 2023-06-06
WO2014089379A1 (en) 2014-06-12
CN107501274A (zh) 2017-12-22
ME03036B (me) 2018-10-20
ES2884030T3 (es) 2021-12-10
JP6401709B2 (ja) 2018-10-10
JP6574859B2 (ja) 2019-09-11
PT3418281T (pt) 2020-12-30
US11370798B2 (en) 2022-06-28
LT2941432T (lt) 2018-06-11
PT2941432T (pt) 2018-06-01
US9340546B2 (en) 2016-05-17
EP3808749A1 (en) 2021-04-21
BR112015012454B1 (pt) 2022-07-05
PL2941432T3 (pl) 2018-09-28
CY1126044T1 (el) 2023-11-15
EP3808749B1 (en) 2023-03-08
CN107629059B (zh) 2020-07-28
US12187731B2 (en) 2025-01-07
AU2013355124A1 (en) 2015-06-18
CN104903325A (zh) 2015-09-09
ZA201503871B (en) 2016-11-30
EP2941432B8 (en) 2018-06-27
RS64234B1 (sr) 2023-06-30

Similar Documents

Publication Publication Date Title
HRP20211034T1 (hr) 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
HRP20191375T1 (hr) Postupak liječenja raka upotrebom kombinacije chk1 i atr inhibitora
JP2014510151A5 (hr)
HRP20171915T1 (hr) Spojevi korisni kao inhibitori atr kinaze i kombinirane terapije koje ih koriste
JP2015515478A5 (hr)
JP2016512815A5 (hr)
JP2016512816A5 (hr)
JP2016512239A5 (hr)
JP2017186385A5 (hr)
JP2016501244A5 (hr)
HRP20180385T1 (hr) Derivati pirazina korisni kao inhibitori atr kinaze
JP2016540773A5 (hr)
CN108771681B (zh) 作为dna-pk抑制剂的化合物及其氘化衍生物的共晶
JP2013526538A5 (hr)
JP2013529200A5 (hr)
JP2013526540A5 (hr)
CN103282037B (zh) 抗肿瘤生物碱的联合治疗
JP2012508260A5 (hr)
JP2013529199A5 (hr)
JP2008530248A5 (hr)
RU2011123647A (ru) Соединения, полезные в качестве ингибиторов atr киназы
Chougule et al. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer
RU2012153675A (ru) Соединения, пригодные в качестве ингибиторов atr киназы
JP2018529713A5 (hr)
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии